BEIJING and INDIANAPOLIS, April 25,
2018 /PRNewswire/ -- Today, Eli Lilly and Company
(NYSE: LLY) and China's National
Center for Cardiovascular Diseases (NCCD) announced plans to
collaborate across four strategic initiatives to advance the
scientific understanding of type 2 diabetes and related
complications, such as cardiovascular disease (CVD), and improve
care for people living with the condition.
In China, the number of people
with diabetes has increased from more than 1 percent of the
population in 1980 to nearly 11 percent in 2017.[i] The
sharp increase in diabetes, including type 2 diabetes, has resulted
in increased complications, such as CVD. In addition, rates of
pre-diabetes continue to climb across the globe, including in
China, where more than 1 in 3
people have pre-diabetes. Less than one-third of people with
diabetes receive treatment.[i]
As a response to this national epidemic, the collaboration
will:
- Evaluate the health economic consequences of diabetes in
China.
- Develop a simple cardiovascular disease (CVD) risk calculator
to improve screening and diabetes management at the primary care
level.
- Analyze patient samples to identify new biomarkers for diabetes
progression, diabetic kidney diseases (DKD), and CVD.
- Develop and distribute medical education for health care
professionals treating diabetes related CVD in China.
To learn more about how these goals will be achieved, watch this
video.
"As the number of people living with diabetes continues to grow
rapidly throughout China, it is
imperative that we address the human and economic impact of the
condition," said Prof Lixin Jiang,
Vice President of Fuwai Hospital, Assistant Director of National
Center for Cardiovascular Diseases. "Diabetes often leads to
complications, including cardiovascular disease. By advancing our
understanding of diabetes and cardiovascular disease, we have an
opportunity to significantly improve care for people in
China."
By 2045, the number of people living with diabetes is expected
to rise to 629 million worldwide, with type 2 diabetes being the
most common form, accounting for around 90 percent of all
cases.[ii] Due to complications associated with
diabetes, CVD is a major complication and the leading cause of
death associated with diabetes.[iii],[iv] Approximately
50 percent of deaths in people with type 2 diabetes worldwide are
caused by CVD.[v],[vi]
The collaboration will leverage data collected by the
Patient-centered Evaluative Assessment of Cardiac Events (PEACE)
Million Persons Project, which is the first large-scale
epidemiological screening in China. The PEACE Million Persons Project will
provide access to data from more than 1 million people with type 2
diabetes and increased CVD risk.
"We are grateful to the NCCD for their willingness to
collaborate with us on initiatives that will advance our
understanding of these complex diseases," said Robert Heine, M.D., Ph.D., Distinguished Lilly
Scholar. "Our hope is this collaboration will produce learning and
tools that will benefit people living with type 2 diabetes in
China and elsewhere around the
world."
About Diabetes
An estimated 425 million adults
worldwide have diabetes.[ii] Type 2 diabetes is the
most common form, accounting for around 90 percent of all
cases.[ii] Diabetes is a chronic disease that occurs
when the body does not properly produce or use the hormone
insulin.
About the National Center for Cardiovascular Diseases
NCCD, set up as a national prevention platform for cardiovascular
disease in 2009, aims to organize and carry out the national
prevention and research. NCCD advocates more partners implementing
the national prevention strategy. For more information, visit
www.nccd.org.cn
About Lilly Diabetes
Lilly has been a global leader
in diabetes care since 1923, when we introduced the world's first
commercial insulin. Today, we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research and collaboration, a wide range
of therapies, and a continued determination to provide real
solutions—from medicines to support programs and more—we strive to
make life better for all those affected by diabetes around the
world. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
http://newsroom.lilly.com/social-channels. P-LLY
i Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern
of diabetes and pre-diabetes in China in 2013. JAMA
2017;317:2515–2523
ii International Diabetes Federation. IDF Diabetes Atlas, 8th edn,
2017. Available at: http://www.diabetesatlas.org/. November
2017.
iii World Health Organisation. Diabetes: Fact Sheet no. 312.
Available at: www.who.int/mediacentre/factsheets/fs312/en/#. Last
accessed March 2018.
iv World Heart Federation. Diabetes as a Risk Factor for
Cardiovascular Disease. Available at:
www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/diabetes.
Last accessed March 2018
v Nwaneri C, et al. Mortality in Type 2 Diabetes Mellitus:
Magnitude of the Evidence from a Systematic Review and
Meta-analysis. The British Journal of Diabetes & Vascular
Disease 2013;13:192–207.
vi Morrish NJ, et al. Mortality and Causes of Death in the WHO
Multinational Study of Vascular Disease in Diabetes. Diabetologia
2001;44(2):S14–21.
Refer to:
Grant Smith; grant.smith@lilly.com;
+1 (317) 954-9907 (Lilly)
Chao Xing; chao.xing@nccd.org.cn;
+(086)010-60866731 (NCCD)
View original content with
multimedia:http://www.prnewswire.com/news-releases/lilly-and-chinas-nccd-announce-collaboration-to-advance-scientific-understanding-and-care-for-people-living-with-diabetes-and-cardiovascular-disease-300635717.html
SOURCE Eli Lilly and Company